title: Advances in amblyopia: what have we learned from PEDIG trials?
abstract: Amblyopia is the most common cause of preventable visual loss in children. This article reviews treatment options, durations, and efficacy in randomized multicentered trials conducted by the Pediatric Eye Disease and Investigator Group in the last decade. Parents and patients should be counseled that many forms of treatment are efficacious, allowing the option of choice of best-tolerated treatment method. Compliance is key to successful treatment. The course of treatment is likely at least 6-12 months, with yearly follow-up suggested once amblyopia has been treated to monitor for regression.
authors: Department of Pediatric Ophthalmology, Wills Eye Institute, Philadelphia, PA 19107, USA. kbgunton@comcast.net
authors: Kammi B
authors: KB
authors: Gunton
mesh_terms: D000550:Amblyopia / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D001285:Atropine / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome; D014786:Vision Disorders / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D001285:Atropine